AI
Saturday, June 03, 2017 10:08:49 AM
PPHM+PerkinElmer ASCO Poster Today: “Prelim-Correlative-Analysis of PD-L1 Expression from the Sunrise Study (Sunrise Biomarker #4)”, 6-3-17 1:15-4:45pm, Chicago.
Jun2-6: “ASCO 2017”, Chicago https://am.asco.org
...PPHM Exhibiting – booth #13124 (next to Moffitt CC)
ASCO’17: PPHM’s 2 Abstracts (11603/June3, e23091/pub.only)
#1: 6-3-17 poster #11603 “Prelim. Corr. Analysis of PD-L1/Expression from SUNRISE” has 11 authors: Lead author is PPHM’s Nikoletta L.Kallinteris, and Senior Author is PerkinElmer’s Technology Strategist Cliff Hoyt, whose function at PKI is to "help identify clinical opportunities that can be addressed through new technologies & capabilities, including forming collaborations & partnerships with academic & industrial institutions.”
#2: Pub. Only (Jrnl Clin. Oncology), “Effect Of Bavituximab In Combination With Nivolumab on Tumor Immune Response in a 3D Ex Vivo System of Lung Cancer Patients”. Senior author is Moffitt’s Soner Altiok (with co-author Moffitt’s Scott Antonia), and Lead author is Nilogen Oncosystems’ Melanie Mediavilla-Varela (see http://www.nilogen.com ).
DETAILS – see: http://tinyurl.com/kkpqvra
=========================
NOTE: 4 Known Sunrise Biomarkers thru 5-2017(ASCO): B2GPI, Complement+IL10, IFN-y, PD-L1 Expr.
Jun2-6: “ASCO 2017”, Chicago https://am.asco.org
...PPHM Exhibiting – booth #13124 (next to Moffitt CC)
ASCO’17: PPHM’s 2 Abstracts (11603/June3, e23091/pub.only)
#1: 6-3-17 poster #11603 “Prelim. Corr. Analysis of PD-L1/Expression from SUNRISE” has 11 authors: Lead author is PPHM’s Nikoletta L.Kallinteris, and Senior Author is PerkinElmer’s Technology Strategist Cliff Hoyt, whose function at PKI is to "help identify clinical opportunities that can be addressed through new technologies & capabilities, including forming collaborations & partnerships with academic & industrial institutions.”
#2: Pub. Only (Jrnl Clin. Oncology), “Effect Of Bavituximab In Combination With Nivolumab on Tumor Immune Response in a 3D Ex Vivo System of Lung Cancer Patients”. Senior author is Moffitt’s Soner Altiok (with co-author Moffitt’s Scott Antonia), and Lead author is Nilogen Oncosystems’ Melanie Mediavilla-Varela (see http://www.nilogen.com ).
DETAILS – see: http://tinyurl.com/kkpqvra
=========================
NOTE: 4 Known Sunrise Biomarkers thru 5-2017(ASCO): B2GPI, Complement+IL10, IFN-y, PD-L1 Expr.
